0001628280-25-048977
SEC filingArteris, Inc. reported revenue growth driven by increased license and royalty revenue, with improved gross margins but ongoing operating losses.
For the three months ended September 30, 2025, Arteris, Inc. reported total revenue of $14.5 million, an increase of 13.3% compared to $12.8 million in the same period of the prior year. This growth was primarily driven by a 18.8% increase in license revenue to $8.2 million, reflecting higher deal volume and larger average deal sizes, and a 12.5% increase in royalty revenue to $4.5 million, attributable to increased shipments of semiconductor products incorporating Arteris' technology. Services revenue declined 10.0% to $1.8 million due to timing of customer engagements.
Gross profit rose to $12.5 million, up 15.7% from $10.8 million in the prior year period, with gross margin expanding to 86.2% from 84.4%. The margin improvement was driven by the favorable revenue mix shift toward higher-margin license revenue. Operating expenses increased modestly, with research and development expenses rising to $8.9 million from $8.5 million, and sales and marketing expenses increasing to $5.2 million from $4.9 million, partially offset by a decrease in general and administrative expenses to $3.6 million from $3.5 million. As a result, operating loss narrowed to $5.2 million from $6.1 million, and net loss improved to $5.0 million from $6.0 million. Net loss per share improved to $(0.14) from $(0.17).
Arteris reports revenue in three segments: License, Royalty, and Services. License revenue, which represented 56.6% of total revenue in the current quarter, grew 18.8% year-over-year, driven by increased adoption of the company's system IP and interconnect solutions. Royalty revenue, accounting for 31.0% of total revenue, grew 12.5%, reflecting strong end-market demand for automotive, mobile, and IoT applications. Services revenue, at 12.4% of total revenue, declined 10.0% due to project timing. The mix shift toward license revenue positively impacted overall gross margins, as license revenue carries higher margins than services.
Management's discussion in the MD&A did not provide specific forward guidance for future periods. However, the company highlighted its focus on expanding its customer base, increasing license deal sizes, and capitalizing on the growing complexity of semiconductor designs. Arteris continues to invest in research and development to enhance its product portfolio and maintain competitive positioning. The company's cash position of $42.1 million as of September 30, 2025, provides a solid foundation to support these strategic initiatives. Management also noted ongoing efforts to manage operating expenses while driving revenue growth, with the goal of achieving improved operating leverage over time.
As of September 30, 2025, Arteris held $17.4M in cash and cash equivalents, $21.6M in short-term investments, and $17.2M in long-term investments, totaling $56.2M in liquidity. The company's stockholders' deficit stood at $(11.4)M, primarily due to accumulated deficit of $(163.1)M offset by paid-in capital of $151.4M. Total debt consisted solely of vendor financing arrangements of $2.2M (current $1.6M, noncurrent $0.6M). Deferred revenue was $85.9M ($46.2M current, $39.6M noncurrent).
The company disclosed no material non-cancelable purchase commitments as of September 30, 2025 (Note 10). Operating lease liabilities totaled $4.6M (current $1.2M, noncurrent $3.4M) with undiscounted cash flows of $5.6M. Vendor financing arrangements had undiscounted cash flows of $2.4M.
Arteris did not engage in share repurchases or pay dividends during the period. Capital expenditures for the nine months ended September 30, 2025 were $1.3M, representing 2.6% of total revenue. Debt repayments under vendor financing totaled $0.9M. No new debt or equity issuance occurred beyond routine stock option exercises and ESPP.
The company operates as a single reportable segment (Note 15). The CODM (CEO) assesses performance using consolidated net loss and other metrics (ACV, RPO). Disaggregated revenue by product type is provided in Note 3, but no geographic revenue breakdown is disclosed in the Notes section (revenue by region appears in MD&A only). Customer concentration: Customer A accounted for 13% of revenue for the three and nine months ended September 30, 2025.
For the nine months ended September 30, 2025, Arteris reported a net loss of $26.2 million, yet generated positive operating cash flow of $3.6 million. This divergence is primarily driven by significant non-cash charges: stock-based compensation of $13.8 million, depreciation and amortization of $2.5 million, and a loss from equity method investment of $2.1 million. Working capital changes also contributed positively, led by a $10.3 million increase in deferred revenue and a $4.1 million reduction in accounts receivable.
Capital expenditures (capex) rose sharply to $1.3 million from $0.3 million in the prior-year period, reflecting increased investment in property and equipment. Free cash flow, though not explicitly stated, is CFO minus capex, which would be approximately $2.3 million for the period.
No share repurchases or dividends were paid. Financing activities provided $1.3 million, driven by stock option exercises ($1.5 million) and employee stock purchase plan proceeds ($0.5 million), partially offset by vendor financing payments ($0.9 million).
Anomaly: A non-cash purchase of property and equipment through vendor financing of $1.7 million is disclosed, indicating capex was higher than the cash outlay suggests. The cash flow statement also notes unrealized gains on available-for-sale securities, but these are not included in the GAAP cash flow statement.